Abstract: The present disclosure relates to an agar hydrolysis product having hyaluronidase inhibitory activity and uses thereof. According to the present disclosure, the agar partial hydrolysis product excellently inhibits the activity of hyaluronidase, which degrades hyaluronic acid (HA), an important factor in skin moisturization, and thus may be variously used in cosmetics, food, or medicine to maintain and enhance skin moisturization, maintain skin elasticity, improve skin wrinkles, as well as promote skin regeneration and prevent aging.

Abstract: The present invention relates to a novel human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein and a use thereof. More particularly, the human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein of the present invention has fused therein: a signal peptide of a Bacillus subtilis-derived xylanase; a human epidermal growth factor (hEGF); and an Escherichia coli-derived trigger factor (TF). Therefore, the present invention not only enhances the water solubility and expression rate of a target protein, but also notably enhances useful effects such as the effects of increasing skin cell growth and healing a wound, and thus may be widely used in various industries as an active ingredient for a functional cosmetic composition and a pharmaceutical composition.